Search - tctmd.com

Displaying 241 - 260 of 357

Sort: Relevancy | Date

Presentation TCT 2016

EXCEL Top Line Results Revisited

Presenter: A. Pieter Kappetein, Marie-Claude Morice, Gregg W. Stone

October 31, 2016

News Industry News

Trial Results Suggest That Drug-Eluting Stents Are Acceptable Alternative To Open Heart Surgery For Select Patients With Left Main Coronary Artery Disease

October 31, 2016

News Conference News TCT 2016

EXCEL y NOBLE: Los Resultados Contrarios Plantean un Dilema a la Hora de Elegir entre PCI y CABG en el Manejo de la Enfermedad de Tronco Coronario Izdo.

Michael O'Riordan

October 31, 2016

News Conference News TCT 2016

EXCEL and NOBLE: Opposing Results Pose Quandary for PCI/CABG Choice in Left Main Disease

Michael O'Riordan

October 31, 2016

Presentation TCT 2016

EXCEL: A Prospective, Randomized Trial Comparing Everolimus-Eluting Stents and Bypass Graft Surgery in Selected Patients With Left Main Coronary Artery Disease

Presenter: Martin B. Leon, Keith G. Oldroyd, Gregg W. Stone

October 31, 2016

News Conference News TCT 2016

Opinions Still Mixed on Bivalirudin vs Heparin for Primary PCI

Yael L. Maxwell

October 31, 2016

News Conference News TCT 2016

BIONICS: Ridaforolimus-Eluting Stent Noninferior to Zotarolimus Stent at 1 Year

TCT Daily Staff

October 30, 2016

Presentation TCT 2016

Should Bivalirudin Only Be Used With a Prolonged Post-PCI Infusion?

Presenter: A. Michael Lincoff, Franz-Josef Neumann, Gregg W. Stone

October 30, 2016

Presentation TCT 2016

BIONICS: A Prospective, Randomized Trial of a Ridaforolimus-Eluting Coronary Stent vs a Zotarolimus-Eluting Stent in a More-Comers Population of Patients With Coronary Artery Disease

Presenter: Gregg W. Stone, Wayne B. Batchelor, David E. Kandzari

October 30, 2016

Presentation TCT 2016

BIO-RESORT (TWENTE III): A Prospective, Randomized Three-Arm Trial Comparing Two Different Biodegradable Polymer-Based Drug-Eluting Stents and a Durable Polymer-Based Drug-Eluting Stent in an All-Comers Population of Patients With Coronary Artery Disease

Presenter: Gregg W. Stone, Wayne B. Batchelor, Clemens von Birgelen

October 30, 2016

News Opinion Editor's Corner TCT 2016

TCT 2016: Inspiration and Perspiration Greet Left Main Stenting, Hoop Dreams, Valve Innovation, and Election Fever

Shelley Wood

October 24, 2016

News Conference News ESC 2016

Day or Night, STEMI Patients Receive Similar Levels of Quality Care

L.A. McKeown

August 31, 2016

News Conference News ESC 2016

NORSTENT: Do Modern-day Bare-Metal Stents Stand Up to Drug-Eluting Stents?

Shelley Wood

August 30, 2016

News Daily News

One Map to Guide Them All: The Physician Who Hopes to Connect the Cardiology Dots

Michael H. Wilson

August 15, 2016

News Daily News

Now You See It: FDA Approves Absorb Bioresorbable Scaffold

Michael O'Riordan

July 05, 2016

News Daily News

Prolonged Full-Dose Bivalirudin May Preserve Bleeding Benefit Without Upping Thrombotic Events After STEMI, Meta-Analysis Suggests

Yael L. Maxwell

June 20, 2016

News Daily News

PCI Continues to Carve Out a Share of Unprotected Left Main Disease in the Absence of Definitive Evidence

Todd Neale

June 08, 2016

Presentation Fellows 2016

Drug-Eluting Stents: Past, Present, and Future

Presenter: Gregg Stone

April 15, 2016

Presentation ACC 2016

Outcomes of the ABSORB Bioresorbable Vascular Scaffold in Very Small and Not Very Small Coronary Arteries: The ABSORB III randomized trial

Presenter: Gregg W. Stone

April 03, 2016

News Daily News

AVB Absorb: Seguridad, Eficacia y Trombosis del Stent a Estudio en 2 Nuevos Análisis

Michael O'Riordan

March 30, 2016

Advertisement

EXCEL Top Line Results Revisited

Trial Results Suggest That Drug-Eluting Stents Are Acceptable Alternative To Open Heart Surgery For Select Patients With Left Main Coronary Artery Disease

EXCEL y NOBLE: Los Resultados Contrarios Plantean un Dilema a la Hora de Elegir entre PCI y CABG en el Manejo de la Enfermedad de Tronco Coronario Izdo.

EXCEL and NOBLE: Opposing Results Pose Quandary for PCI/CABG Choice in Left Main Disease

EXCEL: A Prospective, Randomized Trial Comparing Everolimus-Eluting Stents and Bypass Graft Surgery in Selected Patients With Left Main Coronary Artery Disease

Opinions Still Mixed on Bivalirudin vs Heparin for Primary PCI

BIONICS: Ridaforolimus-Eluting Stent Noninferior to Zotarolimus Stent at 1 Year

Should Bivalirudin Only Be Used With a Prolonged Post-PCI Infusion?

BIONICS: A Prospective, Randomized Trial of a Ridaforolimus-Eluting Coronary Stent vs a Zotarolimus-Eluting Stent in a More-Comers Population of Patients With Coronary Artery Disease

BIO-RESORT (TWENTE III): A Prospective, Randomized Three-Arm Trial Comparing Two Different Biodegradable Polymer-Based Drug-Eluting Stents and a Durable Polymer-Based Drug-Eluting Stent in an All-Comers Population of Patients With Coronary Artery Disease

TCT 2016: Inspiration and Perspiration Greet Left Main Stenting, Hoop Dreams, Valve Innovation, and Election Fever

Day or Night, STEMI Patients Receive Similar Levels of Quality Care

NORSTENT: Do Modern-day Bare-Metal Stents Stand Up to Drug-Eluting Stents?

One Map to Guide Them All: The Physician Who Hopes to Connect the Cardiology Dots

Now You See It: FDA Approves Absorb Bioresorbable Scaffold

Prolonged Full-Dose Bivalirudin May Preserve Bleeding Benefit Without Upping Thrombotic Events After STEMI, Meta-Analysis Suggests

PCI Continues to Carve Out a Share of Unprotected Left Main Disease in the Absence of Definitive Evidence

Drug-Eluting Stents: Past, Present, and Future

Outcomes of the ABSORB Bioresorbable Vascular Scaffold in Very Small and Not Very Small Coronary Arteries: The ABSORB III randomized trial

AVB Absorb: Seguridad, Eficacia y Trombosis del Stent a Estudio en 2 Nuevos Análisis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content